Author:
Tyner Katherine M.,Zheng Nan,Choi Stephanie,Xu Xiaoming,Zou Peng,Jiang Wenlei,Guo Changning,Cruz Celia N.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Tyner KM, Zou P, Yang X, Zhang H, Cruz CN, Lee SL. Product quality for nanomaterials: current U.S. experience and perspective. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. 2015;7(5):640–54.
2. D'Mello, S. R., Cruz, C.N., Chen, M.L., Kapoor, M., Lee, S.L., Tyner, K.M., The evolving landscape of drug products containing nanomaterials in the U.S. Nature Nanotechnology, 2017.
3. Cruz CN, Tyner KM, Velazquez L, Hyams KC, Jacobs A, Shaw AB, Jiang W, Lionberger R, Hinderling P, Kong Y, Brown PC, Ghosh T, Strasinger C, Suarez-Sharp S, Henry D, Van Uitert M, Sadrieh N, Morefield E. CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug products. AAPS J. 2013;15(3):623–8.
4. FDA, U., Q9 Quality Risk Management. 2006.
5. FDA, U., Content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic biotechnology-derived products. 1995.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献